HARmonized protocol template to enhance reproducibility of hypothesis evaluating real world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force

12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...

Read more →

ISPOR launches “About Real-World Evidence” content

8 March 2022 - Introductory information is designed to make RWE more accessible for health care audiences. ...

Read more →

ICER uses observational real world evidence to update 2018 assessment on therapies for hereditary angioedema, finds therapies far less cost effective than earlier estimates

24 August 2021 - Patients initiating therapy in real world dataset had less frequent baseline attack rates than rates from clinical ...

Read more →

Quality, access, and the use of real world data by payers: where are we now? Where do we want to be in the future?

15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases ...

Read more →

ICER to use Aetion observational RWE to update value assessment of treatments for hereditary angioedema

12 April 2021 - New ICER pilot will incorporate more than 24 months of observational real world demographic, utilisation, and cost ...

Read more →

ICER Analytics launched to accelerate the real world application of ICER reports, helping payers, the life science industry, and health care policy makers move from insight to action

30 November 2020 - The Institute for Clinical and Economic Review today formally launched ICER Analytics, a new cloud-based platform that ...

Read more →

Drug pricing review group signs deal with Aetion for patient data

24 February 2020 - The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has ...

Read more →

ICER and Aetion partner to develop real-world evidence for value assessment of treatments

24 February 2020 - ICER adopts Aetion’s Real-World Evidence Platform — advancing standards for the use of transparent, replicable real-world ...

Read more →

ICER publishes guidance on improving the development and use of real world evidence for drug coverage and formulary decisions

10 April 2018 - The ICER, in collaboration with the Office of Health Economics, has released two new white papers to ...

Read more →